5-氧代-5,6,7,8-四氢2-萘酰氯 | 920304-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-氧代-5,6,7,8-四氢2-萘酰氯
• 英文名称: Tetralone-6-carboxamide
• 英文别名: 5-oxo-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid amide；5-Oxo-5,6,7,8-tetrahydronaphthalene-2-carboxamide；5-oxo-7,8-dihydro-6H-naphthalene-2-carboxamide
• CAS: 920304-25-2
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: OVLTZPBVKMLQRW-UHFFFAOYSA-N

物化性质

• 沸点：
  361.6±31.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  60.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  5-氧代-5,6,7,8-四氢2-萘酰氯 、 (4'-Butyl-biphenyl-3-yl)-hydrazine hydrochloride 以similar yield as example 1, step 3.11H NMR (400 MHz, d6-DMSO) δ 11.60 (s, 1H), 7.83 (m, 2H), 7.70 (d, J=8.3 Hz, 1H), 7.59 (m, 3H), 7.27-7.35 (m, 4H), 3.05 (m, 2H), 2.96 (m, 2H), 2.62 (m, 2H), 1.60 (m, 2H), 1.35 (m, 2H), 0.92 (m, 3H)的产率得到9-(4-butylphenyl)-5,11-dihydro-6H-benzo[a]carbazole-3-carboxylic acid amide
  参考文献：
  名称：

  Heterotetracyclic compounds as TPO mimetics

  摘要：

  本发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或调节TPO活性相关的疾病或障碍的方法，特别是涉及血小板减少症的疾病或障碍。

  公开号：

  US08153671B2

文献信息

• HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS
  申请人：Alper Phillip B.

  公开号：US20090075996A1

  公开（公告）日：2009-03-19

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.

  该发明提供了一类新颖的化合物，包括含有这些化合物的药物组合物，以及使用这些化合物来治疗或预防与TPO活性异常或失调相关的疾病或障碍的方法，尤其是涉及血小板减少症的疾病或障碍。
• Selective beta3 adrenergic agonists
  申请人：Rito J. Christopher

  公开号：US20050043337A1

  公开（公告）日：2005-02-24

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I).

  本发明涉及医学领域，特别是治疗II型糖尿病和肥胖症。更具体地，本发明涉及选择性β3受体激动剂，用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病和肥胖症的方法，包括向需要的哺乳动物施用式（I）的化合物。
• Selective B3 adrenergic agonists
  申请人：——

  公开号：US20020165234A1

  公开（公告）日：2002-11-07

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr; 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: 1

  本发明属于医学领域，特别是用于治疗2型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3受体激动剂，用于治疗2型糖尿病和肥胖症。本发明提供了化合物和治疗2型糖尿病和肥胖症的方法，包括向需要此类化合物的哺乳动物施用式I的化合物：1
• Selective beta 3 adrenergic agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0921120A1

  公开（公告）日：1999-06-09

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective b3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: wherein: X1 is -OCH2-, -SCH2-, or a bond; R1 is a heterocycle of the formula: R2 and R3 are independently hydrogen, C1-C4 alkyl, or aryl; R4 is an optionally substituted heterocycle or a moiety selected from the group consisting of: X2 is a bond, or a 1 to 5 carbon straight or branched alkylene; R5 is hydrogen or C1-C4 alkyl; R6 is hydrogen or C1-C4 alkyl; or R5 and R6 combine with the carbon to which each is attached to form a C3-C6 cycloalkyl; or R6 combines with X2 and the carbon to which each is attached to form a C3-C8 cycloalkyl; or R6 combines with X2, R4, and the carbon to which each is attached to form: provided that R5 is hydrogen; R7 is hydrogen, hydroxy, cyano, oxo, COnR2, CONHR2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 optionally substituted alkyl, (CH2)n aryl, (CH2)nheterocycle, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle; R8 is independently hydrogen, halo, or C1-C4 alkyl; R9 is halo, CN, OR10, C1-C4 alkyl, C1-C4 haloalkyl, CO2R2, CONR11R12, CONH(C1-C4 alkyl or C1-C4 alkoxy), SR2, CSNHR2, CSNR11R12, SO2R2, SOR2, NR11R12, optionally substituted aryl, optionally substituted heterocycle, or C2-C4 alkenyl substituted with CN, CO2R2, or CONR11R12; R10 is C1-C4 alkyl, C1-C4 haloalkyl, (CH2)nC3-C8 cycloalkyl, (CH2)naryl, (CH2)nheterocycle, (CH2)nC3-C8 optionally substituted cycloalkyl, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle; R11 and R12 are independently hydrogen, C1-C4 alkyl, aryl, (CH2)naryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R13 is hydrogen, halo, aryl, or C1-C4 alkyl; m is 0 or 1; n is 0, 1, 2, or 3; or a pharmaceutically acceptable salt thereof.

  本发明属于医学领域，特别是 II 型糖尿病和肥胖症的治疗。更具体地说，本发明涉及用于治疗 II 型糖尿病和肥胖症的选择性 b3 受体激动剂。本发明提供了治疗 II 型糖尿病和肥胖症的化合物和方法，包括向需要的哺乳动物施用式 I 的化合物： 其中 X1是-O -、-S -或键； R1 是式中的杂环： R2 和 R3 独立地为氢、C1-C4 烷基或芳基； R4 是任选取代的杂环或选自以下组成的组的分子： X2 是键，或 1 至 5 碳直链或支链亚烷基； R5 是氢或 C1-C4 烷基 R6 是氢或 C1-C4 烷基； 或 R5 和 R6 与各自相连的碳结合形成 C3-C6 环烷基； 或 R6 与 X2 和各自相连的碳结合形成 C3-C8 环烷基； 或 R6 与 X2、R4 和各自相连的碳结合形成： 但 R5 为氢； R7 是氢、羟基、氰基、氧代、COnR2、CONHR2、C1-C4 烷基、C1-C4 烷氧基、C1-C4 卤代烷基、C1-C4 任选取代的烷基、(CH2)n 芳基、( )n 杂环、( )n 任选取代的芳基或 ( )n 任选取代的杂环； R8 独立地为氢、卤代或 C1-C4 烷基； R9 是卤素、CN、OR10、C1-C4 烷基、C1-C4 卤代烷基、CO2R2、CONR11R12、CONH（C1-C4 烷基或 C1-C4 烷氧基）、SR2、CSNHR2、CSNR11R12、SO2R2、SOR2、NR11R12、任选取代的芳基、任选取代的杂环或被 CN、CO2R2 或 CONR11R12 取代的 C2-C4 烯基； R10 是 C1-C4 烷基、C1-C4 卤代烷基、( )nC3-C8 环烷基、( )n 芳基、( )n 异环、( )nC3-C8 任选取代的环烷基、( )n 任选取代的芳基或 ( )n 任选取代的杂环； R11 和 R12 独立地为氢、C1-C4 烷基、芳基、( )芳烷基，或与各自结合的氮结合形成吗啉基、哌啶基、吡咯烷基或哌嗪基； R13 是氢、卤代、芳基或 C1-C4 烷基； m 是 0 或 1； n 是 0、1、2 或 3； 或其药学上可接受的盐。
• Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
  作者：Phil B. Alper、Thomas H. Marsilje、Daniel Mutnick、Wenshuo Lu、Arnab Chatterjee、Michael J. Roberts、Yun He、Donald S. Karanewsky、Donald Chow、Jianmin Lao、Andrea Gerken、Tove Tuntland、Bo Liu、Jonathan Chang、Perry Gordon、H. Martin Seidel、Shin-Shay Tian

  DOI：10.1016/j.bmcl.2008.08.068

  日期：2008.10

  A novel series of benzo[a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor is reported. Starting from a 3.4 mu M high throughput screen hit, members of this series have been identified which are full agonists with functional potency < 50 nM and oral bioavailability in mice. (C) 2008 Elsevier Ltd. All rights reserved.